Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 147 #1
TickerCOCO [NASD]
CompanyCorinthian Colleges Inc.
CountryUSA
IndustryEducation & Training Services
Market Cap9.11MEPS (ttm)-0.84
P/E-EPS this Y5.00%
Forward P/E1.55EPS next Y-30.93%
PEG-EPS past 5Y-10.20%
P/S0.01EPS next 5Y10.00%
P/B0.02EPS Q/Q-
Dividend-Sales Q/Q-11.60%
Insider Own1.70%Inst Own44.50%
Insider Trans-8.74%Inst Trans-32.31%
Short Float28.47%EarningsSep 17
Analyst Recom3.70Target Price-
Avg Volume3.37M52W Range0.13 - 2.54
16-Sep-14 09:07PMU.S. consumer bureau sues Corinthian, alleging predatory lending at Los Angeles Times
16-Sep-14 06:21PMSuit: Corinthian Colleges victimized students at USA TODAY
16-Sep-14 04:45PMGovernment sues Corinthian Colleges for predatory lending CNNMoney.com
16-Sep-14 04:05PMU.S. consumer watchdog accuses Corinthian Colleges of predatory loans Reuters
16-Sep-14 03:44PMCorinthian Colleges sued for predatory lending AP
16-Sep-14 03:20PMFeds sue Corinthian Colleges, alleging predatory lending at Los Angeles Times
16-Sep-14 02:35PMCorinthian Colleges Sued by U.S. Over Predatory Lending at Bloomberg
16-Sep-14 02:33PMRegulators Sue Corinthian Colleges for Allegedly Harassing Low-Income Students at BusinessWeek
16-Sep-14 02:15PMCFPB Sues Corinthian Colleges for Predatory Lending Credit.com
08-Sep-14 02:21PM[video] Education stocks soar at CNBC
Corinthian Colleges, Inc. operates as a post-secondary education company. The company offers various diploma programs, as well as associate, bachelor's, and master's degrees. It also provides training program in healthcare, criminal justice, business, mechanical, trades, and information technology areas. The company's diploma curricula includes medical assisting, medical insurance billing and coding, massage therapy, dental assisting, pharmacy technician, medical administrative assisting, surgical technology, automotive and diesel technology, HVAC, plumbing, electrical, and licensed practical nursing programs. Its degree curriculum comprises business administration, accounting, paralegal, criminal justice, medical assisting, and registered nursing programs. Corinthian Colleges, Inc. also provides online programs in business, criminal justice, criminal investigations, accounting, computer information science, and paralegal. As of June 30, 2013, it operated 97 schools in 25 states of the United States and 14 schools in the province of Ontario, Canada with a total of 81,284 student enrollments under the Everest, WyoTech, and Heald brand names. The company was founded in 1995 and is based in Santa Ana, California.
TickerDLIA [NASD]
CompanydELiA*s, Inc.
CountryUSA
IndustryCatalog & Mail Order Houses
Market Cap16.09MEPS (ttm)-1.04
P/E-EPS this Y-85.50%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-25.60%
P/S0.13EPS next 5Y14.00%
P/B0.39EPS Q/Q40.00%
Dividend-Sales Q/Q-22.60%
Insider Own15.10%Inst Own70.40%
Insider Trans13.16%Inst Trans-4.07%
Short Float23.88%EarningsSep 10
Analyst Recom1.00Target Price2.00
Avg Volume726.47K52W Range0.26 - 1.68
16-Sep-14 05:26PMDELIAS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
16-Sep-14 01:15PMDELiA*s, Inc. (DLIA) Dangerously Close To 52-Week Low at TheStreet
15-Sep-14 04:43PMGeorge Soros Picks KIOR, RSH, BIOL Soar On Monday at TheStreet
11-Sep-14 02:23PMFraud Allegations Dog 21Vianet Group As Share Price Plummets at TheStreet
10-Sep-14 04:28PMDELIAS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
10-Sep-14 04:26PMWhy dELiA*s (DLIA) Stock Is Down in After-Hours Trading Today at TheStreet
10-Sep-14 04:01PMdELiA*s, Inc. Announces Second Quarter Fiscal 2014 Results Business Wire
10-Sep-14 07:07AMQ2 2014 dELiA's Inc. Earnings Release - Time Not Supplied CCBN
03-Sep-14 01:41PMArrowhead Research Climbs +8.54% Midday, Is Up Over +50% YTD at TheStreet
27-Aug-14 04:01PMdELiA*s, Inc. to Report Second Quarter 2014 Results on September 10, 2014 Business Wire
dELiA*s, Inc. operates as a multi-channel retail company, primarily marketing to teenage girls in the United States. The company sells various product categories to consumers through its Website, direct mail catalogs, and retail stores. It develops, markets, and sells a collection of apparel, dresses, swimwear, footwear, outerwear, and accessories primarily for teenage girls under the dELiA*s name. As of May 3, 2014, the company operated 99 stores. It also develops, markets, and sells third-party brands. The company was founded in 1997 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zimmerman MichaelDirectorJun 04Buy0.62100,00061,780283,974Jun 05 08:00 AM
Gardner TracyChief Executive OfficerDec 05Buy1.0110,00010,139998,096Dec 10 04:53 PM
RAFFIN PAUL JDirectorNov 26Buy1.3650,00067,776248,505Nov 27 03:04 PM
TickerSIGA [NASD]
CompanySIGA Technologies, Inc.
CountryUSA
IndustryBiotechnology
Market Cap63.17MEPS (ttm)-0.29
P/E-EPS this Y-22.20%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-2.60%
P/S14.36EPS next 5Y1.00%
P/B5.36EPS Q/Q60.00%
Dividend-Sales Q/Q-69.60%
Insider Own1.30%Inst Own28.20%
Insider Trans27.48%Inst Trans-8.66%
Short Float10.82%EarningsMay 01/a
Analyst Recom1.00Target Price11.00
Avg Volume496.37K52W Range1.22 - 4.15
16-Sep-14 11:14AM[$$] Siga Technologies Files for Bankruptcy Protection at The Wall Street Journal
16-Sep-14 08:26AMSiga Technologies files for Ch 11 reorganization AP
16-Sep-14 08:21AMBiodefense drugmaker Siga files for bankruptcy Reuters
16-Sep-14 07:13AMSiga, Smallpox Drug Supplier to U.S., Files Bankruptcy at Bloomberg
16-Sep-14 07:10AMDrugmaker Siga Technologies files for bankruptcy Reuters
16-Sep-14 06:50AM6:50 am SIGA Technologies files for Chapter 11 reorganization; will ensure that SIGA continues to supply Tecovirimat pursuant to its contract with the Biomedical Advanced Research and Development Authority Briefing.com
16-Sep-14 06:47AMSIGA Technologies, Inc. Files for Chapter 11 Reorganization Business Wire
12-Sep-14 09:03AM4 Under-$10 Stocks to Trade for Breakouts at TheStreet
18-Aug-14 09:09AMAs Ebola Outbreak Expands, These Experimental Drugs Could See Action at Forbes
12-Aug-14 05:29PMSIGA TECHNOLOGIES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
SIGA Technologies, Inc. is engaged in the development and commercialization of pharmaceutical solutions for serious unmet medical needs and biothreats. The company's lead product is Arestvyr, an orally administered antiviral drug that targets orthopoxviruses. It is also developing dengue antiviral and anti-arenavirus drug candidates, which are in pre-clinical stage. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAVAS PAUL GDirectorMay 15Option Exercise0.0015,000091,840May 16 05:51 PM
STERN ANDREW LDirectorMay 15Option Exercise0.0015,000032,150May 16 05:58 PM
TOWNSEND FRANCES FDirectorMay 15Option Exercise0.0015,000032,000May 16 06:04 PM
BAYER MICHAEL JDirectorMay 15Option Exercise0.0015,000030,000May 16 04:57 PM
Bevins William CDirectorMay 15Option Exercise0.0015,000080,000May 16 05:07 PM
TickerLEDS [NASD]
CompanySemiLEDs Corporation
CountryUSA
IndustrySemiconductor- Memory Chips
Market Cap14.52MEPS (ttm)-1.32
P/E-EPS this Y12.20%
Forward P/E-EPS next Y-
PEG-EPS past 5Y0.00%
P/S0.93EPS next 5Y50.00%
P/B0.30EPS Q/Q42.50%
Dividend-Sales Q/Q31.40%
Insider Own11.00%Inst Own9.20%
Insider Trans19.99%Inst Trans-5.04%
Short Float0.52%EarningsJul 14/a
Analyst Recom2.00Target Price3.00
Avg Volume102.01K52W Range0.62 - 1.66
29-Aug-14 06:01AMSEMILEDS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tra EDGAR Online
26-Aug-14 09:52PMNew Chip Scale ReadyMount(TM) EC LED Series From SemiLEDs GlobeNewswire
21-Aug-14 10:49PMSemiLEDs Launches EF FlipChip LED Series GlobeNewswire
13-Aug-14 10:48PMSemiLEDs Releases Complete 80mil EV LED Chip Family GlobeNewswire
25-Jul-14 04:06PMSEMILEDS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
19-Jul-14 01:04PMSEMILEDS CORP Financials EDGAR Online Financials
15-Jul-14 10:40AMSEMILEDS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
14-Jul-14 04:05PMSEMILEDS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
14-Jul-14 04:01PMSemiLEDs Reports Third Quarter Fiscal Year 2014 Financial Results Business Wire
14-Jul-14 07:07AMQ3 2014 SemiLEDs Corp Earnings Release - After Market Close CCBN
SemiLEDs Corporation develops, manufactures, and sells light emitting diode (LED) chips and LED components. Its products are used primarily for general lighting applications, including street lights and commercial, industrial, and residential lighting, as well as specialty industrial applications, such as ultraviolet (UV) applications, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, and architectural lighting applications. The company markets and sells blue, green, and UV LED and enhanced vertical LED chips under the MvpLED brand name to packagers, or distributors that sell to packaging customers in China, Taiwan, Russia, and the United States. It also packages its LED chips into LED components and sells to distributors and end-customers. SemiLEDs Corporation was incorporated in 2005 and is based in Chunan, Taiwan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DOAN TRUNG TChairman and CEOMay 08Buy1.0220,00020,4002,079,555May 12 07:00 AM
Tuttle Mark EwingGM of SemiLEDs OptoelectronicsApr 17Buy1.1012,00013,184270,000Apr 21 08:05 PM
TickerOMEX [NASD]
CompanyOdyssey Marine Exploration Inc.
CountryUSA
IndustryBusiness Services
Market Cap76.71MEPS (ttm)-0.05
P/E-EPS this Y48.00%
Forward P/E-EPS next Y-
PEG-EPS past 5Y23.60%
P/S3.24EPS next 5Y-
P/B10.00EPS Q/Q64.30%
Dividend-Sales Q/Q0.00%
Insider Own0.40%Inst Own41.80%
Insider Trans27.72%Inst Trans-15.01%
Short Float25.64%EarningsMay 13/b
Analyst Recom2.00Target Price5.00
Avg Volume752.30K52W Range1.05 - 3.18
16-Sep-14 08:50AM8:50 am Odyssey Marine Exploration completes current phase of SS Central America recovery Briefing.com
16-Sep-14 08:47AMOdyssey Marine Exploration Completes Current Phase of SS Central America Recovery GlobeNewswire
09-Sep-14 08:30AM"Don Diego" Project Achieves Important Milestone GlobeNewswire
19-Aug-14 01:04PMODYSSEY MARINE EXPLORATION INC Financials EDGAR Online Financials
18-Aug-14 08:32AMODYSSEY MARINE EXPLORATION INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct F EDGAR Online
14-Aug-14 09:45AMODYSSEY MARINE EXPLORATION INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement EDGAR Online
14-Aug-14 09:00AMLooking to Invest in Unusual Businesses? Accesswire
11-Aug-14 04:33PMOdyssey Marine Exploration Reports Second Quarter 2014 Results GlobeNewswire
11-Aug-14 04:19PMODYSSEY MARINE EXPLORATION INC Files SEC form 10-Q, Quarterly Report EDGAR Online
06-Aug-14 08:00AMOdyssey Marine Exploration Sets Second Quarter 2014 Conference Call for Monday, August 11, 2014 at 4:45 p.m. ET GlobeNewswire
Odyssey Marine Exploration, Inc., together with its subsidiaries, is engaged in the archaeologically sensitive exploration and recovery of deep-ocean shipwrecks worldwide. Its shipwreck projects include various activities, such as research of historical records and academic materials; search operations; archaeological pre-disturbance survey, and archaeological excavation and recovery; conservation, recording, documentation, and publication/exhibition; surgical removal of deck plates or ship structures; cargo salvage; and commercial monetization of recovered cargo. The company also conducts deep-ocean mineral exploration; and sells coins, bullion, and other mass-produced cargo to collectors, as well as cultural collections of artifacts to museums and other institutions. Odyssey Marine Exploration, Inc. was founded in 1986 and is headquartered in Tampa, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAUL DAVID JDirectorOct 18Buy2.6344,540117,1401,061,006Oct 22 09:14 AM
TickerOPXA [NASD]
CompanyOpexa Therapeutics, Inc.
CountryUSA
IndustryBiotechnology
Market Cap30.81MEPS (ttm)-0.83
P/E-EPS this Y18.80%
Forward P/E-EPS next Y3.60%
PEG-EPS past 5Y22.60%
P/S22.01EPS next 5Y-
P/B2.27EPS Q/Q59.50%
Dividend-Sales Q/Q0.00%
Insider Own3.45%Inst Own6.00%
Insider Trans0.63%Inst Trans-2.57%
Short Float2.24%EarningsNov 11
Analyst Recom2.00Target Price5.00
Avg Volume155.67K52W Range1.25 - 2.56
16-Sep-14 08:36AMOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
16-Sep-14 08:36AM8:36 am Opexa Therapeutics announces termination of public offering of common stock Briefing.com
16-Sep-14 08:30AMOpexa Therapeutics, Inc. Announces Termination of Public Offering of Common Stock Business Wire
15-Sep-14 04:25PMOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
15-Sep-14 04:21PMOpexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Business Wire
08-Sep-14 07:30AMOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
08-Sep-14 07:29AMOpexa Therapeutics to Target Rare Disease Neuromyelitis Optica (NMO) as next Development Program Business Wire
02-Sep-14 09:00AMOpexa Therapeutics to Present at September Conferences Business Wire
22-Aug-14 01:04PMOPEXA THERAPEUTICS, INC. Financials EDGAR Online Financials
14-Aug-14 04:23PMOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure EDGAR Online
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) based on its proprietary T-cell technology. Its product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seaman Scott BDirectorDec 18Buy1.7030,00051,00040,913Dec 18 03:58 PM
Radhakrishnan KarthikChief Financial OfficerDec 18Buy1.708,00013,60058,000Dec 18 03:55 PM
TickerSPEX [NASD]
CompanySpherix Incorporated
CountryUSA
IndustryBusiness Services
Market Cap29.32MEPS (ttm)-11.02
P/E-EPS this Y-29.40%
Forward P/E-EPS next Y-
PEG-EPS past 5Y29.50%
P/S1047.00EPS next 5Y-
P/B0.29EPS Q/Q39.50%
Dividend-Sales Q/Q-
Insider Own0.20%Inst Own5.70%
Insider Trans60.28%Inst Trans19.26%
Short Float7.59%EarningsAug 30
Analyst Recom3.00Target Price1.00
Avg Volume938.26K52W Range1.12 - 13.70
16-Sep-14 04:47PMVirnetX to Vringos Lost Millions Show Patent Peril at Bloomberg
02-Sep-14 06:00AMUnited States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix PR Newswire
25-Aug-14 06:00AMFirst Trial of Nortel Patents Since Bankruptcy Scheduled Against Verizon for First Quarter of 2015 PR Newswire
22-Aug-14 01:04PMSPHERIX INC Financials EDGAR Online Financials
13-Aug-14 04:47PMSPHERIX INC Files SEC form 10-Q, Quarterly Report EDGAR Online
29-Jul-14 06:00AMPatent Monetization Strategy Now Includes Nine Litigation Programs as Spherix Continues to Identify Infringers of Its IP PR Newswire
24-Jul-14 06:00AMSpherix Schedules Shareholder Update Call PR Newswire
10-Jul-14 12:47PMSPHERIX INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
20-Jun-14 10:10AMSPHERIX INC Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online
19-Jun-14 06:00AMSpherix CEO to Speak at the IP Business Congress Global 2014 Conference PR Newswire
Spherix Incorporated operates as an intellectual property company that owns patented and unpatented intellectual properties. The company owns approximately 330 patents and patent applications. Its patent portfolio includes the U.S. and foreign patents and pending patent applications in the wireless communications and telecommunication sectors, including data, optical and voice technology, antenna technology, Wi-Fi, base station functionality, and cellular, as well as patents related to artificial sweetener and prescription refill technology. The company was founded in 1967 and is based in Tysons Corner, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hayes AnthonyCHIEF EXECUTIVE OFFICERJun 09Buy1.692,5004,22529,581Jun 10 12:12 PM
Hayes AnthonyCHIEF EXECUTIVE OFFICERApr 11Buy2.354,0009,40027,081Apr 11 03:54 PM
Kesner Harvey JDirectorApr 03Buy2.8410,00028,39513,700Apr 03 05:46 PM
Kesner Harvey JDirectorApr 01Buy3.102,0006,2082,000Apr 01 02:06 PM
Kesner Harvey JDirectorApr 01Buy3.152,7008,5023,700Apr 01 02:06 PM
TickerCLRB [NASD]
CompanyCellectar Biosciences, Inc.
CountryUSA
IndustryBiotechnology
Market Cap20.51MEPS (ttm)-3.59
P/E-EPS this Y15.00%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-1.40%
Dividend-Sales Q/Q-
Insider Own3.50%Inst Own4.80%
Insider Trans-Inst Trans-2.15%
Short Float0.01%Earnings-
Analyst Recom-Target Price-
Avg Volume18.05K52W Range2.95 - 9.20
08-Sep-14 01:12PMCELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
05-Sep-14 08:30AMCellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September GlobeNewswire
04-Sep-14 08:30AMCellectar Biosciences Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma GlobeNewswire
26-Aug-14 10:07AMCELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
20-Aug-14 04:15PMCellectar Biosciences Reports Second Quarter 2014 Financial Results and Recent Highlights GlobeNewswire
20-Aug-14 04:05PMCellectar Biosciences Announces Closing of Public Offering and Partial Exercise of Underwriter's Over-Allotment Option GlobeNewswire
20-Aug-14 01:18PMCELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
19-Aug-14 01:04PMCELLECTAR BIOSCIENCES, INC. Financials EDGAR Online Financials
18-Aug-14 04:15PMCellectar Biosciences to Host Conference Call on August 20th to Discuss Second Quarter 2014 Results and Provide Quarterly Update on Development Progress GlobeNewswire
14-Aug-14 07:39PMCellectar Biosciences Announces Pricing of $12,500,000 Public Offering and Listing on The Nasdaq Capital Market GlobeNewswire
Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
TickerSRNE [NASD]
CompanySorrento Therapeutics, Inc.
CountryUSA
IndustryBiotechnology
Market Cap140.94MEPS (ttm)-1.57
P/E-EPS this Y-247.60%
Forward P/E-EPS next Y8.40%
PEG-EPS past 5Y0.00%
P/S74.18EPS next 5Y-
P/B1.60EPS Q/Q5.70%
Dividend-Sales Q/Q700.00%
Insider Own-Inst Own46.70%
Insider Trans-Inst Trans96.47%
Short Float1.20%Earnings-
Analyst Recom2.00Target Price20.67
Avg Volume84.93K52W Range4.75 - 16.40
05-Sep-14 08:45AMSorrento Therapeutics to Present at Two Healthcare Conferences PR Newswire
02-Sep-14 01:50PMSRNE: NIH Provides Funding for Sorrentos Immunotherapy Targeting Idiopathic Pulmonary Fibrosis Zacks Small Cap Research
29-Aug-14 02:16AMTwo Portfolios. Pick One. Yahoo Finance Blogs
26-Aug-14 08:45AMSorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) PR Newswire
21-Aug-14 04:41PMSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
19-Aug-14 01:04PMSORRENTO THERAPEUTICS, INC. Financials EDGAR Online Financials
18-Aug-14 04:44PMSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
18-Aug-14 07:45AMData Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics PR Newswire
12-Aug-14 11:30AMSorrento (SRNE): Valuation Is Attractive Zacks Small Cap Research
08-Aug-14 05:06PMSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial St EDGAR Online
Sorrento Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. Its lead product candidate, Cynviloq, is a micellar diblock copolymeric paclitaxel formulation currently approved and marketed in various countries, including South Korea, for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), and ovarian cancer under the trade name Genexol-PM. Cynviloq has also completed Phase I or III trials for MBC, and Phase I or II trials in NSCLC, Ovarian, Bladder, and Pancreatic cancers. The company is also developing resiniferatoxin, a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease. In addition, the company is also developing antibody drug conjugates and recombinant intravenous immunoglobulin (rIVIG) for the treatment of certain auto-immune diseases, as well as immunodeficiencies. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
TickerCHOP [NASD]
CompanyChina Gerui Advanced Materials Group Ltd.
CountryChina
IndustrySteel & Iron
Market Cap21.36MEPS (ttm)-0.32
P/E-EPS this Y-153.30%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-18.50%
P/S0.16EPS next 5Y12.50%
P/B0.07EPS Q/Q-
Dividend-Sales Q/Q-42.10%
Insider Own50.48%Inst Own2.70%
Insider Trans-Inst Trans-21.59%
Short Float1.65%EarningsNov 27/b
Analyst Recom2.00Target Price4.00
Avg Volume75.12K52W Range0.40 - 1.82
04-Sep-14 08:00AMChina Gerui Advanced Materials Group Limited Announces Unaudited Second Quarter 2014 Financial Results PR Newswire
02-Sep-14 04:00PMChina Gerui Announces Resignation from Board of Director PR Newswire
25-Aug-14 04:00PMChina Gerui Advanced Materials Group Limited Announces Conference Call to Discuss Unaudited Second Quarter 2014 Financial Results PR Newswire
06-Jun-14 04:01PMChina Gerui Advanced Materials Group Limited Announces Share Repurchase Update PR Newswire
06-Jun-14 04:00PMChina Gerui Advanced Materials Group Limited Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Rule PR Newswire
02-Jun-14 08:00AMChina Gerui Advanced Materials Group Limited Sponsors the AMM Steel Success Strategies XXIX Conference PR Newswire
29-May-14 08:03AMChina Gerui announces CEO share repurchase plan theflyonthewall.com
29-May-14 08:03AMChina Gerui announces CEO share repurchase plan at theflyonthewall.com
29-May-14 08:00AMChina Gerui Advanced Materials Group Limited Announces CEO Share Purchase Plan PR Newswire
28-May-14 08:05AMChina Gerui resumes share repurchase program at theflyonthewall.com
China Gerui Advanced Materials Group Limited operates as a contract manufacturer of cold-rolled narrow strip steel products in the People's Republic of China and internationally. The company converts steel manufactured by third parties into thin steel sheets and strips. It primarily serves food and industrial packaging, construction and household decorations materials, electrical appliances, and telecommunications wires and cables industries. The company sells its products directly to manufacturers or through distributors. The company was formerly known as Golden Green Enterprises Limited and changed its name to China Gerui Advanced Materials Group Limited in December 2009. China Gerui Advanced Materials Group Limited is based in Zhengzhou, the People's Republic of China.
1 2 3 4 5 6 ... 10 ... 15 next